1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. STOKE THERAPEUTICS INC

Stoke Therapeutics Inc XNAS: STOK

Stoke Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Weak Stock
Download real time

8.15 -0.18 (-2.16%)

53.64% Fall from 52W High

1.4M XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Board Meeting
The next board meeting for Stoke Therapeutics Inc is on 25 Mar 2025 for the purpose of Stoke Therapeutics Inc Fourth Quarter Earnings Results for 2024 See details

Stoke Therapeutics Inc Key Metrics

Default

Market Capitalization

Below industry Median
440.7

PE TTM

Negative PE TTM
-5

PEG TTM

Negative PEG TTM
-0.3

Price to Book

Below industry Median
1.9

Institutional holding current Qtr %

High in industry
103.8

Revenue Growth Qtr YoY %

High in industry
707.1

Operating Revenue growth TTM %

High in industry
316.3

Net Profit Qtr Growth YoY %

High in industry
61.1

Net Profit TTM Growth %

Below industry Median
15

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-277.3

Piotroski Score

Low in industry
1

Rel Perf vs Sector quarter%

-36.8
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
5.6 / 100
Valuation Score
Expensive Valuation
12.8 / 100
Momentum Score
Technically Bearish
32.7 / 100
Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
24
1Yr Price target upside is 193%
8 analysts

9

S

15

W

1

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Stoke Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '260100200Actual RevenueAvg. Estimate
Hit

Stoke Therapeutics Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

Current EPS
-1.6
Avg. Estimate
-1.2
Low Estimate
-2.4
High Estimate
1.1
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 26.7% in FY25

Consensus Recommendation

10 ANALYST Recommendations
STRONG BUY

Created with Highcharts 7.2.21Hold2Buy7Strong Buy

The consensus recommendation from 10 analysts for Stoke Therapeutics Inc is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Stoke Therapeutics Inc Stock Analysis

Stoke Therapeutics Inc stock analysis with key metrics, changes, and trends.

Stoke Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$36.56 M316.34%positive

Annual Revenue rose 316.34%, in the last year to $36.56 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit$88.98 M15.01%positive

Annual Net Profit rose 15.01% in the last year to $88.98 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio-4.95-negative

Price to Earning Ratio is -4.95, which is negative.

Stock Price$8.1529.37%positive

Stock Price rose 29.37% and outperformed its sector by 20.3% in the past year.

Quarterly Revenue$22.61 M707.07%positive

Quarterly Revenue rose 707.07% YoY to $22.61 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$10.48 M61.12%positive

Quarterly Net profit rose 61.12% YoY to $10.48 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

Mutual Fund Holding28.49 %-0.59%negative

Mutual Fund Holding decreased by 0.59% in the last quarter to 28.49.

Promoter Share Holding2.04 %0.21%positive

Promoter Share Holding increased by 0.21% in the most recent quarter to 2.04%.

Institutional Holding103.79 %0%neutral

Institutional Holding remained the same in the last quarter at 103.79%.

VIEW LESS


Loading data..

Stoke Therapeutics Inc - Company Profile

What does Stoke Therapeutics Inc do?

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Stoke Therapeutics Inc Management structure

All Gross Remunerations are in USD
Mr. Stephen J. Tulipano
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. Thomas E. Leggett
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Dr. Huw M. Nash, PhD
Chief Business Officer
-
2024
Gross Remuneration
Year
Mr. Ian F. Smith
Director and Interim Chief Executive Officer
-
2024
Gross Remuneration
Year

Stoke Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Mr. Ian F. Smith
Director and Interim Chief Executive Officer
-
2024
Gross Remuneration
Year
Dr. Arthur A. Levin,PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Seth L. Harrison, M.D.
Independent Director
-
2024
Gross Remuneration
Year
Dr. Edward M. Kaye, M.D.
Director
-
2024
Gross Remuneration
Year
Ms. Julie Anne Smith
Independent Director
-
2024
Gross Remuneration
Year
Dr. Garry E. Menzel, PhD
Independent Director
-
2024
Gross Remuneration
Year

Stoke Therapeutics Inc FAQ

How is Stoke Therapeutics Inc today?
Stoke Therapeutics Inc today is trading in the red, and is down by -2.16% at 8.15.
Stoke Therapeutics Inc is currently trading down -2.16% on an intraday basis. In the past week the stock fell -5.23%. stock has been down -28.19% in the past quarter and rose 29.37% in the past year. You can view this in the overview section.